Selected research
Industry Growth & Trends
Global Mycosis Fungoides Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Mycosis Fungoides Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Mycosis Fungoides Therapeutics market include Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck & Co. Inc., Soligenix Inc., Seattle Genetics Inc., Horizon Therapeutics Plc, Helsinn Healthcare SA and Celgene Corp., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Mycosis Fungoides Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Mycosis Fungoides Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Mycosis Fungoides Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Mycosis Fungoides Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Mycosis Fungoides Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Mycosis Fungoides Therapeutics Market by Company
Kyowa Kirin Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Eisai Co. Ltd.
Merck & Co. Inc.
Soligenix Inc.
Seattle Genetics Inc.
Horizon Therapeutics Plc
Helsinn Healthcare SA
Celgene Corp.
Azurity Pharmaceuticals Inc.
Mycosis Fungoides Therapeutics Segment by Type
Small Molecules
Biologics
Mycosis Fungoides Therapeutics Segment by Application
Hospital
Clinic
Other
Mycosis Fungoides Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycosis Fungoides Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mycosis Fungoides Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycosis Fungoides Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Mycosis Fungoides Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecules
- Biologics
Applications
- Hospital
- Clinic
- Other
Companies covered
- Kyowa Kirin Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Eisai Co. Ltd.
- Merck & Co. Inc.
- Soligenix Inc.
- Seattle Genetics Inc.
- Horizon Therapeutics Plc
- Helsinn Healthcare SA
- Celgene Corp.
- Azurity Pharmaceuticals Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Mycosis Fungoides Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Mycosis Fungoides Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Mycosis Fungoides Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Mycosis Fungoides Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 1.5.1 North America Mycosis Fungoides Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Mycosis Fungoides Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Mycosis Fungoides Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Mycosis Fungoides Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Mycosis Fungoides Therapeutics Market Size Growth Rate (2021-2032)
2 Mycosis Fungoides Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Small Molecules
- 2.1.2 Biologics
- 2.2 Global Mycosis Fungoides Therapeutics Market Size by Type
- 2.2.1 Global Mycosis Fungoides Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Mycosis Fungoides Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Mycosis Fungoides Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Mycosis Fungoides Therapeutics Market Size by Regions
- 2.3.1 North America Mycosis Fungoides Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Mycosis Fungoides Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Mycosis Fungoides Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Mycosis Fungoides Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Mycosis Fungoides Therapeutics Market Size Breakdown by Type (2021-2026)
3 Mycosis Fungoides Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Other
- 3.2 Global Mycosis Fungoides Therapeutics Market Size by Application
- 3.2.1 Global Mycosis Fungoides Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Mycosis Fungoides Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Mycosis Fungoides Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Mycosis Fungoides Therapeutics Market Size by Regions
- 3.3.1 North America Mycosis Fungoides Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Mycosis Fungoides Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Mycosis Fungoides Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Mycosis Fungoides Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Mycosis Fungoides Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Mycosis Fungoides Therapeutics Industry Trends
- 4.2 Mycosis Fungoides Therapeutics Industry Drivers
- 4.3 Mycosis Fungoides Therapeutics Industry Opportunities and Challenges
- 4.4 Mycosis Fungoides Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Mycosis Fungoides Therapeutics Revenue (2021-2026)
- 5.2 Global Mycosis Fungoides Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Mycosis Fungoides Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Mycosis Fungoides Therapeutics Company, Product Type & Application
- 5.5 Global Mycosis Fungoides Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Mycosis Fungoides Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Mycosis Fungoides Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Mycosis Fungoides Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Kyowa Kirin Co. Ltd.
- 6.1.1 Kyowa Kirin Co. Ltd. Company Information
- 6.1.2 Kyowa Kirin Co. Ltd. Business Overview
- 6.1.3 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 6.1.5 Kyowa Kirin Co. Ltd. Recent Developments
- 6.2 Takeda Pharmaceutical Co. Ltd.
- 6.2.1 Takeda Pharmaceutical Co. Ltd. Company Information
- 6.2.2 Takeda Pharmaceutical Co. Ltd. Business Overview
- 6.2.3 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 6.2.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
- 6.3 Eisai Co. Ltd.
- 6.3.1 Eisai Co. Ltd. Company Information
- 6.3.2 Eisai Co. Ltd. Business Overview
- 6.3.3 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 6.3.5 Eisai Co. Ltd. Recent Developments
- 6.4 Merck & Co. Inc.
- 6.4.1 Merck & Co. Inc. Company Information
- 6.4.2 Merck & Co. Inc. Business Overview
- 6.4.3 Merck & Co. Inc. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.4.5 Merck & Co. Inc. Recent Developments
- 6.5 Soligenix Inc.
- 6.5.1 Soligenix Inc. Company Information
- 6.5.2 Soligenix Inc. Business Overview
- 6.5.3 Soligenix Inc. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.5.5 Soligenix Inc. Recent Developments
- 6.6 Seattle Genetics Inc.
- 6.6.1 Seattle Genetics Inc. Company Information
- 6.6.2 Seattle Genetics Inc. Business Overview
- 6.6.3 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.6.5 Seattle Genetics Inc. Recent Developments
- 6.7 Horizon Therapeutics Plc
- 6.7.1 Horizon Therapeutics Plc Company Information
- 6.7.2 Horizon Therapeutics Plc Business Overview
- 6.7.3 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio
- 6.7.5 Horizon Therapeutics Plc Recent Developments
- 6.8 Helsinn Healthcare SA
- 6.8.1 Helsinn Healthcare SA Company Information
- 6.8.2 Helsinn Healthcare SA Business Overview
- 6.8.3 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio
- 6.8.5 Helsinn Healthcare SA Recent Developments
- 6.9 Celgene Corp.
- 6.9.1 Celgene Corp. Company Information
- 6.9.2 Celgene Corp. Business Overview
- 6.9.3 Celgene Corp. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio
- 6.9.5 Celgene Corp. Recent Developments
- 6.10 Azurity Pharmaceuticals Inc.
- 6.10.1 Azurity Pharmaceuticals Inc. Company Information
- 6.10.2 Azurity Pharmaceuticals Inc. Business Overview
- 6.10.3 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.10.5 Azurity Pharmaceuticals Inc. Recent Developments
7 North America
- 7.1 North America Mycosis Fungoides Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Mycosis Fungoides Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Mycosis Fungoides Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Mycosis Fungoides Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Mycosis Fungoides Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Mycosis Fungoides Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Mycosis Fungoides Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Mycosis Fungoides Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Mycosis Fungoides Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Mycosis Fungoides Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst